心活素对慢性充血性心力衰竭患者NT-proBNP水平、不良反应的影响

Effect of Cardiopeptin on NT-proBNP Levels,Adverse Reactions in Pa⁃tients with Chronic Congestive Heart Failure

目的分析心活素对慢性充血性心力衰竭患者N-末端脑钠肽前体(N-terminal pro-Brain Natriuretic Peptide,NT-proBNP)水平、不良反应的影响。方法选取2020年2月—2023年3月梁山县人民医院收治的100例慢性充血性心力衰竭患者为研究对象,按随机数表法分成对照组(托拉塞米+螺内酯+缬沙坦美托洛尔缓释片)和观察组(在对照组基础上联合注射用重组人脑利钠肽),各50例,并对两组患者治疗后的NT-proBNP水平、不良反应等指标进行比较分析。结果治疗后,观察组左心室射血分数高于对照组;左心室收缩末期内径、左心室收缩期整体纵向应变、缺血节段和全左室左前降支支配区域纵向应变、左心室舒张末期内径评分低于对照组,差异有统计学意义(P均<0.05);治疗后观察组患者的NT-proBNP水平(580.21±17.71)ng/L低于对照组(603.32±18.89)ng/L,差异有统计学意义(t=6.251,P<0.05),观察组不良反应发生率(10.00%)与对照组(6.00%)比较,差异无统计学意义(P>0.05)。结论心活素对慢性充血性心力衰竭患者治疗的效果更好,用药后患者的NT-proBNP水平更低,且患者心功能水平更高,不良反应发生率低,该治疗方式的综合应用价值更高。

Objective To analyze the effects of cardiopeptin on N-terminal pro-brain natriuretic peptide(NT-proBNP)levels,adverse reactions in patients with chronic congestive heart failure.Methods 100 patients with chronic congestive heart failure admitted to Liangshan County People's Hospital from February 2020 to March 2023 were the study subjects,and were divided into the control group(torasemide+spironolactone+valacyclovir extended-release tablets)and the observation group(combined with injection of recombinant human brain natriuretic peptide on the ba⁃sis of the control group)by random number table method with 50 cases in each group.And the NT-proBNP level,ad⁃verse reactions and other indexes of the two groups after treatment were compared and analyzed.Results After treat⁃ment,the left ventricular ejection fraction of the observation group was higher than that of the control group,and the left ventricular end-systolic dimension,global longitudinal strain,totall longitudinal strain and left ventricular end-diastolic dimension scores were lower than those of the control group,and the differences were statistically significant(all P<0.05).The NT-proBNP level of patients in the observation group(580.21±17.71)ng/L was lower than that of the control group(603.32±18.89)ng/L after treatment,and the difference was statistically significant(t=6.251,P<0.05),and there was no statistical significance difference of the incidence of adverse reactions in the observation group(10.00%)and the control group(6.00%)(P>0.05).Conclusion The effect of cardiopeptin on the treatment of patients with chronic congestive heart failure is better,the NT-proBNP level of the patients is lower,and the cardiac function level of the patients is higher,and the incidence of adverse reactions is low,and the comprehensive application of this treatment is of higher value.